Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy

Journal of Hepatology

Volumn 53, Issue 4, 2010, Pages 677-685

  Van Der Bij, Gerben J ^a   Bögels, Marijn ^a   Otten, Marielle A ^b   Oosterling, Steven J ^a   Kuppen, Peter J ^b   Meijer, Sybren ^a   Beelen, Robert H J ^a   Van Egmond, Marjolein ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ADCC; Antibody therapy; Colorectal cancer; Kupffer cell; Macrophage; Metastasis; Phagocytosis; Surgery

Indexed keywords

IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT PHAGOCYTOSIS; ANTIBODY SPECIFICITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOMA CELL; CELL CYCLE ARREST; CELL INTERACTION; CELL VIABILITY; COCULTURE; COLON CARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HYBRIDOMA; INNATE IMMUNITY; KUPFFER CELL; LIVER METASTASIS; LOW DRUG DOSE; MALE; MONOCYTE; MONONUCLEAR PHAGOCYTE; NONHUMAN; PHAGOCYTOSIS; PORTAL VEIN BLOOD FLOW; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, MONOCLONAL; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; PHAGOCYTES; PHAGOCYTOSIS; TREATMENT OUTCOME;

EID: 77956262454     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2010.04.023     Document Type: Article

References (38)

1. S.J. Oosterling, G.J. van der Bij, M. Bogels, S.T. Raa, J.A. Post, and G.A. Meijer Anti-β1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces Ann Surg 247 2008 85 94
2. J.C. Coffey, J.H. Wang, M.J. Smith, D. Bouchier-Hayes, T.G. Cotter, and H.P. Redmond Excisional surgery for cancer cure: therapy at a cost Lancet Oncol 4 2003 760 768
3. G.J. van der Bij, S.J. Oosterling, M. Bogels, F. Bhoelan, D.M. Fluitsma, and R.H. Beelen Blocking α2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth Hepatology 47 2008 532 543
4. T.G. Allen-Mersh, T.K. McCullough, H. Patel, R.Q. Wharton, C. Glover, and S.K. Jonas Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma Br J Surg 94 2007 96 105
5. K. Yamaguchi, Y. Takagi, S. Aoki, M. Futamura, and S. Saji Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection Ann Surg 232 2000 58 65
6. N.C. Bird, D. Mangnall, and A.W. Majeed Biology of colorectal liver metastases: a review J Surg Oncol 94 2006 68 80
7. J. Xu, Y. Zhong, N. Weixin, Q. Xinyu, L. Yanhan, and R. Li Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery Ann Surg 245 2007 583 590
8. S. Sadahiro, T. Suzuki, K. Ishikawa, S. Yasuda, T. Tajima, and H. Makuuchi Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial Cancer 100 2004 590 597
9. G.P. Adams, and L.M. Weiner Monoclonal antibody therapy of cancer Nat Biotechnol 23 2005 1147 1157
10. D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, and A. Santoro Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
11. G. Riethmuller, E. Holz, G. Schlimok, W. Schmiegel, R. Raab, and K. Hoffken Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial J Clin Oncol 16 1998 1788 1794
12. M.A. Chaudry, K. Sales, P. Ruf, H. Lindhofer, and M.C. Winslet EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges Br J Cancer 96 2007 1013 1019
13. S. Li, K.R. Schmitz, P.D. Jeffrey, J.J. Wiltzius, P. Kussie, and K.M. Ferguson Structural basis for inhibition of the epidermal growth factor receptor by cetuximab Cancer Cell 7 2005 301 311
14. M. Imai, C. Landen, R. Ohta, N.K. Cheung, and S. Tomlinson Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer Cancer Res 65 2005 10562 10568
15. R. Clynes, Y. Takechi, Y. Moroi, A. Houghton, and J.V. Ravetch Fc receptors are required in passive and active immunity to melanoma Proc Natl Acad Sci USA 95 1998 652 656
16. W.K. Weng, and R. Levy Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma J Clin Oncol 21 2003 3940 3947
17. I. Bergman, P.H. Basse, M.A. Barmada, J.A. Griffin, and N.K. Cheung Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors Cancer Immunol Immunother 49 2000 259 266
18. M.A. Otten, G.J. van der Bij, S.J. Verbeek, F. Nimmerjahn, J.V. Ravetch, and R.H. Beelen Experimental antibody therapy of liver metastases reveals functional redundancy between FcγRI and FcγRIV J Immunol 181 2008 6829 6836
19. M. Hagenaars, R. Koelemij, N.G. Ensink, J.D. van Eendenburg, R.L. van Vlierberghe, and A.M. Eggermont The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma Clin Exp Metastasis 18 2000 281 289
20. K.A. Gelderman, J. Hakulinen, M. Hagenaars, P.J. Kuppen, S. Meri, and A. Gorter Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model Mol Immunol 40 2003 13 23
21. J.H. Boot, M.E. Geerts, E.R. De Groot, and L.A. Aarden Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining J Immunol Methods 106 1988 195 202
22. M.S. Zedeck, and S.S. Sternberg A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate J Natl Cancer Inst 53 1974 1419 1421
23. R.J. Tushinski, I.T. Oliver, L.J. Guilbert, P.W. Tynan, J.R. Warner, and E.R. Stanley Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy Cell 28 1982 71 81
24. N. van Rooijen, N. Kors, M. Ende, and C.D. Dijkstra Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate Cell Tissue Res 260 1990 215 222
25. L.G. Bayon, M.A. Izquierdo, I. Sirovich, N. van Rooijen, R.H. Beelen, and S. Meijer Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver Hepatology 23 1996 1224 1231
26. F. Nimmerjahn, and J.V. Ravetch Divergent immunoglobulin g subclass activity through selective Fc receptor binding Science 310 2005 1510 1512
27. J. Uchida, Y. Hamaguchi, J.A. Oliver, J.V. Ravetch, J.C. Poe, and K.M. Haas The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy J Exp Med 199 2004 1659 1669
28. M.X. Sliwkowski, J.A. Lofgren, G.D. Lewis, T.E. Hotaling, B.M. Fendly, and J.A. Fox Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) Semin Oncol 26 1999 60 70
29. M. Liljefors, B. Nilsson, A.L. Hjelm Skog, P. Ragnhammar, H. Mellstedt, and J.E. Frodin Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A Int J Cancer 105 2003 717 723
30. S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, and G. Gatti Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2 Cancer Res 67 2007 11991 11999
31. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 2000 443 446
32. L. Bevaart, M.J. Jansen, M.J. van Vugt, J.S. Verbeek, J.G. van de Winkel, and J.H. Leusen The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma Cancer Res 66 2006 1261 1264
33. F. Nimmerjahn, P. Bruhns, K. Horiuchi, and J.V. Ravetch FcγRIV: a novel FcR with distinct IgG subclass specificity Immunity 23 2005 41 51
34. D. Shan, J.A. Ledbetter, and O.W. Press Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol Immunother 48 2000 673 683
35. M. Timmers, K. Vekemans, D. Vermijlen, K. Asosingh, P. Kuppen, and L. Bouwens Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis Int J Cancer 112 2004 793 802
36. M.R. Wilson, K.P. O'Dea, D. Zhang, A.D. Shearman, N. van Rooijen, and M. Takata Role of lung-marginated monocytes in an in vivo mouse model of ventilator-induced lung injury Am J Respir Crit Care Med 179 2009 914 922
37. A.K. Mels, M.G. Statius Muller, P.A. van Leeuwen, B.M. von Blomberg, R.J. Scheper, and M.A. Cuesta Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma Br J Surg 88 2001 539 544
38. B. Schuurman, G. Heuff, R.H. Beelen, and S. Meyer Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/ macrophage-colony-stimulating factor and interferon gamma Cancer Immunol Immunother 39 1994 179 184